Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008188 | 0.81 | EPHX1 (0.46) | EPHX1CHRM1HDAC8MEN1KMT2A | |
| SCHEMBL622955 | 0.74 | LMNA (0.62) | EPHX1MEN1KMT2ASLC6A9 | |
| SCHEMBL621911 | 0.70 | EPHX1 (0.73) | EPHX1CHRM1MEN1KMT2AUBE2N | |
| SCHEMBL28609672 | 0.69 | EPHX1 (0.71) | EPHX1CHRM1MEN1KMT2AUBE2N | |
| SCHEMBL29608984 | 0.69 | EPHX1 (0.71) | EPHX1CHRM1MEN1KMT2AUBE2N | |
| SCHEMBL1516139 | 0.68 | EPHX1 (1.00) | EPHX1CHRM1UBE2N | |
| SCHEMBL11019097 | 0.68 | EPHX1 (0.73) | EPHX1CHRM1UBE2N | |
| SCHEMBL10269752 | 0.68 | EPHX1 (0.73) | EPHX1CHRM1CPB2UBE2N | |
| SCHEMBL8620330 | 0.67 | EPHX1 (0.96) | EPHX1CHRM1MEN1KMT2AUBE2N | |
| SCHEMBL28605536 | 0.67 | EPHX1 (0.71) | EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256701-A1 | PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | KCNT1, CEPT1, PIGT | EPHX1 1478/4885CHRM1 1905/4885CPB2 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.